Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.52 |
| ▸ | ALB | P02768 | 3/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | EPOR | P19235 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13880567 | 0.85 | GLP1R (0.62) | GLP1RALBFOLH1 | |
| SCHEMBL25465163 | 0.85 | GLP1R (0.62) | GLP1RALBFOLH1 | |
| SCHEMBL25651302 | 0.85 | GLP1R (0.45) | GLP1RALBFOLH1MEN1KMT2A | |
| SCHEMBL26059894 | 0.85 | GLP1R (0.56) | GLP1RFOLH1EPOR | |
| SCHEMBL16257635 | 0.84 | GLP1R (0.47) | GLP1RTSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL24483719 | 0.84 | GLP1R (0.59) | GLP1RTSHR | |
| SCHEMBL19135688 | 0.84 | GLP1R (0.59) | GLP1RTSHR | |
| SCHEMBL22627100 | 0.84 | GLP1R (0.58) | GLP1RALBFOLH1 | |
| SCHEMBL24483688 | 0.83 | GLP1R (0.70) | GLP1RFOLH1 | |
| SCHEMBL21243011 | 0.83 | GLP1R (0.60) | GLP1RFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527900-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2016-12-27 | — | — | US | disclosed |
| US-20160083447-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083447-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | GLP1R, IAPP, SLC5A1 | GLP1R 1/4885ALB 22/4885FOLH1 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.